Nice PR event for IMU.

First 3379 Last

Share
Profile

Follow
Footmax

13,960 Posts.

2376

26/10/21

12:14

Post #: 57076715
Share

Nice PR event for IMU.

Originally posted by Agent-86: ↑

If interested, put this event into your diary. LC will be presenting on Imugene at 11:10am.

When
Thu, Nov 4, 2021 · 9:00 AMSydney (GMT 11:00)
Agenda
9am
The investment thesis
Expert investors unpack why, when and how to invest in ASX-listed biotechs. This discussion will help you understand potential risks and rewards through the clinical trial phase through commercialisation, the benefits of partnerships and M&A potential.
9:35am
Showcase: Immutep
Global leaders in immunotherapy drugs for cancer and autoimmune diseases, Immutep has four product candidates and is partnered with Novartis and GlaxoSmithKline.
10am
Showcase: Telix
Headquartered in Melbourne with operations in Europe, the US and Japan, Telix is developing a broad portfolio of diagnostic and therapeutic assets using nuclear medicine.
10:25am
Showcase: Opthea
With its lead product candidate in Phase 3 clinical trials, Opthea is developing novel therapies to treat highly prevalent and progressive retinal diseases.
10:50am
Showcase: Volpara
Volpara’s breast health software platform identifies early-stage breast cancer, with its breast density technology used in more than 39 countries.
11:10am
Showcase: Imugene
With three novel technology platforms, Imuegene aims to activate the immune system of cancer patients to identify and eradicate tumors.
11:30am
Valuation masterclass
Biotechnology companies vary greatly, and so do the methods and metrics used to value them. This whiteboard session will help you better understand how and why biotechs are valued as they are, and where to ascribe value going forward.
12pm
Close
Throughout the event you’ll be introduced to six ASX-listed biotechs making their mark. You’ll hear where they are on their path to commercialisation, and find out what they expect to achieve next. Agenda is subject to change

Expand

IMU Price at posting: 47.8¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

CU6

Clarity progresses SECuRE trial with positive safety results

3 stocks with antimony news on Thursday

CHN

Chalice jumps on Putin nickel export ban threat – but then there's bad news

GTR

GTI extends uranium mineralisation at Lo Hema through development drilling

DXB

Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3